https://scholars.lib.ntu.edu.tw/handle/123456789/487388
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | KUN-HUEI YEH | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.creator | Chih-Hung Hsu;Yeh K.-H.;Cheng A.-L. | - |
dc.date.accessioned | 2020-04-28T07:25:41Z | - |
dc.date.available | 2020-04-28T07:25:41Z | - |
dc.date.issued | 1997 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030937624&partnerID=40&md5=7746973eff1f67a7094b9aa3ae3245d1 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/487388 | - |
dc.description.abstract | Thymic carcinoma is known for its poor clinical outcome and unsatisfactory response to conventional chemotherapy. A 53-year-old woman was diagnosed as having metastatic thymic carcinoma in 1989. She received systemic chemotherapy containing cisplatin, doxorubicin, and cyclophosphamide, and involved-field radiotherapy. A durable complete remission was achieved and lasted for 4 years. When the disease recurred in 1995, she was found to have an autoimmune syndrome in addition to pleural effusion, a posterior mediastinal mass and a left adrenal mass. The autoimmune manifestations were seen as sclerodenna, high titers of rheumatoid factor and anti-nuclear antibody. We adopted a novel HDFL regimen, which is composed of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin, for this patient. Complete remission was achieved again, and autoimmune syndrome was well controlled. | en_US |
dc.relation.ispartof | Anticancer Research | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antinuclear antibody; cisplatin; cyclophosphamide; doxorubicin; fluorouracil; folinic acid; rheumatoid factor; adrenal tumor; adult; article; autoimmunity; cancer recurrence; cancer regression; case report; complication; drug therapy; female; human; human tissue; intravenous drug administration; mediastinum mass; oral drug administration; pleura effusion; priority journal; scleroderma; thymus cancer; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Thymus Neoplasms | - |
dc.title | Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin | en_US |
dc.type | journal article | en |
dc.identifier.pmid | 9137493 | - |
dc.identifier.scopus | 2-s2.0-0030937624 | - |
dc.relation.pages | 1331-1334 | en_US |
dc.relation.journalvolume | 17 | en_US |
dc.relation.journalissue | 2B | en_US |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-7306-174X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。